Lynne Hohlfeld
SVP, General Manager for Molecular Diagnostic Division
Learn More
Lynne Hohlfeld
SVP, General Manager for Molecular Diagnostic Division
Lynne Hohlfeld was appointed Senior Vice President and General Manager of the Molecular Diagnostics Division in December 2021. Ms. Hohlfeld joined Bio-Techne as Vice President of Business Development with the acquisition of Asuragen in April 2021, where she served as Chief Financial Officer and SVP of Corporate Development for 12 years. Prior to Asuragen, Ms. Hohlfeld was Chief Financial Officer of Opexa Therapeutics, a public company focused in cell therapy. Ms. Hohlfeld has a long history of strategy, corporate partnerships and financial management for emerging growth companies in life science.
Ms. Hohlfeld holds a Bachelor of Business Administration from the University of Wisconsin – Madison.
Tom Copa
VP, Commercial MDD
Learn More
Tom Copa
VP, Commercial MDD
Mr. Copa joined in 2018 bringing extensive commercial leadership experience in health care and molecular diagnostics. He was most recently vice president of licensed technologies at the Luminex Corporation. In total, Tom spent over 16 years at Luminex as a senior executive in roles spanning sales, marketing, and business development in their clinical and life sciences divisions. He also brings with him over seven years of direct sales experience within the medical device market at Baxter Healthcare (now a part of Cardinal Health). Tom received his B.B.A. in Political Science from Marquette University.
Bernard F. Andruss, PhD
Chief Operating Officer & Head of Companion Diagnostics
Learn More
Bernard F. Andruss, PhD
Chief Operating Officer & Head of Companion Diagnostics
Dr. Andruss joined in March 2006. Bernard has significant R&D experience from his progressive roles at Ambion, Inc. where he helped initiate new R&D projects and expanded Ambion’s SBIR funding program. He assisted in the spinoff of Asuragen from Ambion and built a sponsored research program that has been awarded over $25M in funding. During his tenure at Asuragen, Bernard was responsible for leading many successful diagnostic product development programs. Prior to Ambion, he worked in progressive roles at in academia at Rice University and the University of Texas M. D. Anderson Cancer Center. Dr. Andruss received his Ph.D. in Biochemistry and Cell Biology from Rice University and his B.S. in Biochemistry from Texas A&M University.
Gary J. Latham, PhD
Chief Scientific Officer
Learn More
Gary J. Latham, PhD
Chief Scientific Officer
Dr. Latham joined in March 2006 when Asuragen was founded. Gary has significant R&D leadership experience spanning protein engineering, assay development, and sample prep development at Ambion, Inc., where he launched multiple life science products. During his tenure at Asuragen, he has led the company’s bioinformatics and research groups and was responsible for developing Asuragen’s AmplideX® PCR technology for fragile X syndrome and QuantideX® NGS products for oncology applications. Gary is an inventor on 10 issued and multiple pending patents and has received >$13M in research grants. Dr. Latham received his Ph.D. in Biochemistry from Vanderbilt University, and was an American Cancer Society Postdoctoral Fellow at the University of Oregon’s Institute for Molecular Biology.